
Genelux Corporation (NASDAQ:GNLX – Free Report) – Brookline Capital Markets reduced their FY2026 earnings estimates for shares of Genelux in a research note issued on Monday, November 16th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will earn ($0.85) per share for the year, down from their prior forecast of ($0.80). The consensus estimate for Genelux’s current full-year earnings is ($0.80) per share. Brookline Capital Markets also issued estimates for Genelux’s Q4 2026 earnings at ($0.21) EPS and FY2027 earnings at ($0.58) EPS.
A number of other equities analysts have also weighed in on GNLX. Benchmark reiterated a “speculative buy” rating on shares of Genelux in a report on Tuesday, August 18th. Wall Street Zen upgraded Genelux from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 20th. Lucid Cap Mkts upgraded Genelux to a “strong-buy” rating in a report on Wednesday, September 16th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.
Genelux Stock Performance
Shares of GNLX stock opened at $2.24 on Thursday. Genelux has a one year low of $1.77 and a one year high of $5.89. The company has a 50 day moving average price of $2.29 and a 200 day moving average price of $2.64. The firm has a market capitalization of $101.34 million, a price-to-earnings ratio of -2.55 and a beta of 0.68.
Genelux (NASDAQ:GNLX – Get Free Report) last released its earnings results on Monday, November 16th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03).
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP acquired a new stake in shares of Genelux in the second quarter worth $35,000. Strive Financial Group LLC lifted its holdings in shares of Genelux by 728.7% during the 2nd quarter. Strive Financial Group LLC now owns 41,437 shares of the company’s stock valued at $125,000 after acquiring an additional 36,437 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Genelux by 30.4% during the 3rd quarter. Goldman Sachs Group Inc. now owns 59,727 shares of the company’s stock valued at $151,000 after acquiring an additional 13,918 shares in the last quarter. Trek Financial LLC acquired a new position in shares of Genelux during the 3rd quarter valued at $158,000. Finally, AMG National Trust Bank purchased a new stake in Genelux during the 2nd quarter worth $227,000. 37.33% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In other news, CEO Thomas Zindrick sold 34,463 shares of Genelux stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $2.67, for a total value of $92,016.21. Following the transaction, the chief executive officer directly owned 1,226,427 shares of the company’s stock, valued at $3,274,560.09. The trade was a 2.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Yong Yu sold 9,683 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $2.75, for a total value of $26,628.25. Following the sale, the insider owned 258,688 shares of the company’s stock, valued at $711,392. The trade was a 3.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 47,903 shares of company stock worth $126,320 over the last ninety days. Corporate insiders own 7.50% of the company’s stock.
Genelux Company Profile
Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.
Read More
- Five stocks we like better than Genelux
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
